Do specific antifibrotic properties of immunosuppressive drugs used in the treatment of systemic sclerosis exist?;Existe-t-il une action antifibrosante spécifique des immunosuppresseurs utilisés pour traiter la sclérodermie systémique ?

Revue de Medecine Interne

Volumn 30, Issue 11, 2009, Pages 955-962

  Verrecchia, F ^a,b   Michel, L ^b   Keshtmand, H ^c   Wang, Y ^b,d   Launay, D ^e   Farge, D ^b,c  

^a UNIVERSITÉ DE NANTES   (France)

^b INSERM   (France)

^c SAINT LOUIS HOSPITAL   (France)

^d CHONGQING UNIVERSITY CANCER HOSPITAL   (China)

^e LILLE UNIVERSITY HOSPITAL   (France)

Author keywords

Autologous hematopoietic stem cell transplantation; Collagen; Extracellular matrix; Immunosuppressive drugs; Systemic sclerosis; Tissue fibrosis

Indexed keywords

AZATHIOPRINE; COLLAGEN TYPE 1; COLLAGEN TYPE 3; CORTICOSTEROID DERIVATIVE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; CYTOKINE; IMMUNOSUPPRESSIVE AGENT; INTERSTITIAL COLLAGENASE; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PLACEBO; PLASMINOGEN ACTIVATOR INHIBITOR 1; RAPAMYCIN; SCLEROPROTEIN; THYMOCYTE ANTIBODY; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TRANSFORMING GROWTH FACTOR BETA;

ANTIINFLAMMATORY ACTIVITY; CLINICAL TRIAL; DISEASE SEVERITY; DRUG UTILIZATION; HEART MUSCLE FIBROSIS; HUMAN; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; INTESTINAL FIBROSIS; KIDNEY FIBROSIS; LUNG FIBROSIS; MOLECULAR MECHANICS; PROTEIN SYNTHESIS INHIBITION; SHORT SURVEY; SYSTEMIC SCLEROSIS; TREATMENT OUTCOME;

EID: 72049099632     PISSN: 02488663     EISSN: 17683122     Source Type: Journal    
DOI: 10.1016/j.revmed.2009.02.019     Document Type: Short Survey

References (61)

1. Furst D.E., and Clements P.J. Hypothesis for the pathogenesis of systemic sclerosis. J Rheumatol 48 Suppl. (1997) 53-75
2. Denton C.P., and Black C.M. Targeted therapy comes of age in scleroderma. Trends Immunol 26 (2005) 596-602
3. Abraham D.J., Eckes B., Rajkumar V., and Krieg T. New developments in fibroblast and myofibroblast biology: implications for fibrosis and scleroderma. Curr Rheumatol Rep 9 (2005) 136-143
4. Abraham D.J., and Varga J. Scleroderma: from cell and molecular mechanisms to disease models. Trends Immunol 11 (2005) 587-595
5. Varga J., and Abraham D. Systemic sclerosis: a prototypic multisystem fibrotic disorder. J Clin Invest 117 (2007) 557-567
6. Varga J.A., and Trojanowska M. Fibrosis in systemic sclerosis. Rheum Dis Clin North Am 34 (2008) 115-143
7. Myllyharju J., and Kivirikko K.I. Collagens and collagen-related diseases. An Med 33 (2001) 7-21
8. Verrecchia F., and Mauviel A. TGF-β and TNF-α: antagonistic cytokines controlling type I collagen gene expression. Cell Signal 16 (2004) 873-880
9. Ghosh A.K. Factors involved in the regulation of type I collagen gene expression: implication in fibrosis. Exp Biol Med (Maywood) 227 (2004) 301-314
10. Derk C.T., and Jimenez S.A. Systemic sclerosis: current views of its pathogenesis. Autoimmun Rev 2 (2003) 181-191
11. Verrecchia F., Mauviel A., and Farge D. TGF-β signalling through the Smad proteins: role in systemic sclerosis. Autoimmun Rev 5 (2006) 563-569
12. Verrecchia F., and Mauviel A. TGF-β signalling through the Smad pathway: role in extracellular matrix gene expression and regulation. J Invest Dermatol 118 (2002) 211-215
13. Verrecchia F., and Mauviel A. TGF-β and fibrosis. World J Gastroenterol 13 (2007) 3056-3062
14. Uitto J., and Kouba D. Cytokine modulation of extracellular matrix gene expression: relevance to fibrotic skin diseases. J Dermatol Sci 24 (2000) S60-S69
15. Catania J.M., Chen G., and Parrish A.R. Role of matrix metalloproteinases in renal pathophysiologies. Am J Physiol Renal Physiol 292 (2007) F905-F911
16. Pardo A., and Selman M. MMP-1: the elder of the family. Int J Biochem Cell Biol 37 (2005) 283-288
17. Sato S., Hayakawa I., Hasegawa M., Fujimoto M., and Takehara K. Function blocking autoantibodies against matrix metalloproteinase-1 in patients with systemic sclerosis. J Invest Dermatol 120 (2003) 542-547
18. Takeda K., Hatamochi A., Ueki H., Nakata M., and Oishi Y. Decreased collagenase expression in cultured systemic sclerosis fibroblasts. J Invest Dermatol 103 (1994) 359-363
19. Verrecchia F., Chu M.L., and Mauviel A. Identification of novel TGF-β/Smad gene targets in dermal fibroblasts using a combined cDNA microarray/promoter transactivation approach. J Biol Chem. 276 (2001) 17058-17062
20. Denton C.P., and Abraham D.J. TGF-β and CTGF: key cytokines in scleroderma pathogenesis. Curr Opin Rheumatol 13 (2001) 505-511
21. Dong C., Zhu S., Wang T., Yoon W., Li Z., Alvarez R.J., et al. Deficient Smad7 expression: a putative molecular defect in scleroderma. Proc Natl Acad Sci U S A 99 (2002) 3908-3913
22. Verrecchia F., Laboureau J., Verola O., Roos N., Porcher R., Bruneval P., et al. Skin involvement in scleroderma: where histological and clinical scores meet. Rheumatology (Oxford) 46 (2007) 833-841
23. Mori Y., Chen S.J., and Varga J. Expression and regulation of intracellular SMAD signalling in scleroderma skin fibroblasts. Arthritis Rheum 48 (2003) 1964-1978
24. Denton C.P., Merkel P.A., Furst D.E., Khanna D., Emery P., Hsu V.M., et al. Recombinat human anti-TGF-β1 antibody therapy in SSc: a randomized, placebo-controlled phase I/II trila of CAT-192. Arthritis Rheum 56 (2007) 323-333
25. Xavier S., Piek E., Fujii M., Javelaud D., Mauviel A., Flanders K.C., et al. Amelioration of radiation-induced fibrosis: inhibition of transforming growth factor-beta signaling by halofuginone. J Biol Chem 279 (2004) 15167-15176
26. McGaha T.L., Phelps R.G., Spiera H., and Bona C. Halofuginone, an inhibitor of type-I collagen synthesis and skin sclerosis, blocks transforming-growth-factor-beta-mediated Smad3 activation in fibroblasts. J Invest Dermatol 118 (2002) 461-470
27. Tacheau C., Michel L., Farge D., Mauviel A., and Verrecchia F. Involvement of ERK signaling in halofuginone-driven inhibition of fibroblast ability to contract collagen lattices. Eur J Pharmacol 573 (2007) 65-69
28. Wendling J., Marchand A., Mauviel A., and Verrecchia F. 5-fluorouracil blocks transforming growth factor-beta-induced alpha 2 type I collagen gene (COL1A2) expression in human fibroblasts via c-Jun NH2-terminal kinase/activator protein-1 activation. Mol Pharmacol 64 (2003) 707-713
29. Verrecchia F., Wagner E.F., and Mauviel A. Distinct involvement of the Jun-N-terminal kinase and NF-kappaB pathways in the repression of the human COL1A2 gene by TNF-alpha. EMBO Rep 3 (2002) 1069-1074
30. Verrecchia F., Tacheau C., Wagner E.F., and Mauviel A. A central role for the JNK pathway in mediating the antagonistic activity of pro-inflammatory cytokines against transforming growth factor-beta-driven SMAD3/4-specific gene expression. J Biol Chem 278 (2003) 1585-1593
31. Daniels C.E., Wilkes M.C., Edens M., Kottom T.J., Murphy S.J., Limper A.H., et al. Imatinib mesylate inhibits the profibrogenic activity of TGF-beta and prevents bleomycin-mediated lung fibrosis. J Clin Invest 114 (2004) 1308-1316
32. Taïeb A., Constans J., and Mahon F.X. Une nouvelle piste thérapeutique pour les sclérodermies graves : le mésylate d'imatinib. Rev Med Interne. 29 (2008) 173-175
33. Distler J.H., Jüngel A., Huber L.C., Schulze-Horsel U., Zwerina J., Gay R.E., et al. Imatinib mesylate reduces production of extracellular matrix and prevents development of experimental dermal fibrosis. Arthritis Rheum 56 (2007) 311-322
34. Clements P., Lachenbruch P., Siebold J., White B., Weiner S., Martin R., et al. Inter- and intraobserver variability of total skin thickness score (modified Rodnan TSS) in systemic sclerosis. J Rheumatol 2 (1995) 1281-1285
35. Denton C.P. Renal manifestations of systemic sclerosis-clinical features and outcome assessment. Rheumatology (Oxford) 47 Suppl. 5 (2008) v54-v56
36. Steen V.D., and Medsger Jr. T.A. Case-control study of corticosteroids and other drugs that either precipitate or protect from the development of scleroderma renal crisis. Arthritis Rheum. 41 (1998) 1613-1619
37. Steen V.D., and Medsger Jr. T.A. Severe organ involvement in systemic sclerosis with diffuse scleroderma. Arthritis Rheum 43 (2000) 2437-2444
38. Steen V.D., and Medsger T.A. Changes in causes of death in systemic sclerosis, 1972-2002. Ann Rheum Dis 66 (2007) 940-944
39. Scussel-Lonzetti L., Joyal F., Raynauld J.P., Roussin A., Rich E., Goulet J.R., et al. Predicting mortality in systemic sclerosis: analysis of a cohort of 309 French Canadian patients with emphasis on features at diagnosis as predictive factors for survival. Medicine 81 (2002) 154-167
40. Avouac J, Kowel-Bieleka O, Landewe, Chwiesko S, Miniati I, Czirjak L, et al., On behalf of EUSTAR centers EULAR/EUSTAR Recommendations for the Treatment of Systemic Sclerosis: Methods of elaboration and results of systemic literature research. Ann Rheum Dis.(published on line 28 October).
41. Kowal-Bielecka O, Landewé R, Avouac J, Chwiesko S, Miniati I, Czirjak L, et al. EULAR/EUSTAR Recommendations for treatment of Systemic Sclerosis Ann Rheum Dis 2009. (Epub ahead of print) PMID 19147617.
42. van den Hoogen F.H., Boerbooms A.M., Swaak A.J., Rasker J.J., van Lier H.J., and van de Putte L.B. Comparison of methotrexate with placebo in the treatment of systemic sclerosis: a 24-week randomized double-blind trial, followed by a 24-week observational trial. Br J Rheumatol 35 (1996) 364-372
43. Pope J.E., Bellamy N., Seibold J.R., Baron M., Ellman M., Carette S., et al. A randomized, controlled trial of methotrexate versus placebo in early diffuse scleroderma. Arthritis Rheum 44 (2001) 1351-1358
44. Arakawa H., Yamasaki M., Kurihara Y., Yamada H., and Nakajima Y. Methotrexate induced pulmonary injury: serial CT findings. J Thorac Imaging 18 (2003) 231-236
45. Allison A.C., and Eugui A.M. Mycophenolate mofetil and its mechanisms of action. Immunopharmacology 47 (2000) 85-118
46. Roos N., Poulalhon N., Farge D., Madelaine I., Mauviel A., and Verrecchia F. In vitro evidence for a direct antifibrotic role of the immunosuppressive drug mycophenolate mofetil. J Pharmacol Exp Ther 321 (2007) 583-589
47. Stratton R.J., Wilson H., and Black C.M. Pilot study of anti-thymocyte globulin plus mycophenolate mofetil in recent-onset diffuse scleroderma. Rheumatology (Oxford) 40 (2001) 84-88
48. Liossis S.N., Bounas A., and Andonopoulos A.P. Mycophenolate mofetil as first-line treatment improves clinically evident early scleroderma lung disease. Rheumatology (Oxford) 45 (2006) 1005-1008
49. Swigris J.J., Olson A.L., Fischer A., Lynch D.A., Cosgrove G.P., Frankel S.K., et al. Mycophenolate mofetil is safe, well tolerated, and preserves lung function in patients with connective tissue disease-related interstitial lung disease. Chest 130 (2006) 30-36
50. Nihtyanova S.I., Brough G.M., Black C.M., and Denton C.P. Mycophenolate mofetil in diffuse cutaneous systemic sclerosis: a retrospective analysis. Rheumatology (Oxford) 46 (2007) 442-445
51. Brown E.J., Albers M.W., Shin T.B., Ichikawa K., Keith C.T., Lane W.S., et al. A mammalian protein targeted by G1-arresting rapamycin-receptor complex. Nature 369 (1994) 756-758
52. Shegogue D., and Trojanowska M. Mammalian target of rapamycin positively regulates collagen type I production via a phosphatidylinositol 3-kinase-independent pathway. J Biol Chem 279 (2004) 23166-23175
53. Poulalhon N., Farge D., Roos N., Tacheau C., Neuzillet C., Michel L., et al. Modulation of collagen and MMP-1 gene expression in fibroblasts by the immunosuppressive drug rapamycin. A direct role as an antifibrotic agent?. J Biol Chem 281 (2006) 33045-33052
54. Lytton S.D., Denton C.P., and Nutzenberger A.M. Treatment of autoimmune disease with rabbit anti-T lymphocyte globulin: clinical efficacy and potential mechanisms of action. Ann NY Acad Sci 1110 (2007) 285-296
55. Tashkin D.P., Elashoff R., Clements P.J., Goldin J., Roth M.D., Furst D.E., et al. Scleroderma Lung Study Research Group. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med 354 (2006) 2655-2666
56. Tashkin D.P., Elashoff R., Clements P.J., Roth M.D., Furst D.E., Silver R.M., et al. Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease. Am J Respir Crit Care Med 176 (2007) 1026-1034
57. Hoyles R.K., Ellis R.W., Wellsbury J., Lees B., Newlands P., Goh N.S., et al. A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma. Arthritis Rheum 54 (2006) 3962-3970
58. Vonk M.C., Marjanovic Z., van den Hoogen F.H., Zohar S., Schattenberg A.V., Fibbe W.E., et al. Long-term follow-up results after autologous haematopoietic stem cell transplantation for severe systemic sclerosis. Ann Rheum Dis 67 (2008) 98-104
59. Nash R.A., McSweeney P.A., Crofford L.J., Abidi M., Chen C.S., Godwin J.D., et al. High-dose immunosuppressive therapy and autologous hematopoietic cell transplantation for severe systemic sclerosis: long-term follow-up of the US multicenter pilot study. Blood 110 (2007) 1388-1396
60. Verrecchia F., and Farge D. HSCT: A step foward in treatment of SSc. Blood 110 (2007) 1088-1089
61. van Laar J.M., Farge D., and Tyndall A. Stem cell transplantation: a treatment option for severe systemic sclerosis?. Ann Rheum Dis 67 (2008) 13